Patients with TP53 and RB1 mutations but not CDKN2A had worse OS than that of patients who did not: 1‐year OS: 96.4% (95% CI: 0.90–1.0) vs. 57.7% (95% CI: 0.32–0.84) for TP53, p = 0.016; 88.3% (95% CI: 0.77–0.99) vs. 50.0% (95% CI: 0.10–0.90), p = 0.0037 for RB1; 83.3% (95% CI: 0.70–0.97) vs. 80.0% (95% CI: 0.55–1.0), p = 0.36 for CDKN2A in patients with metastatic or advanced sarcoma who received CGP test before initial systemic treatment (Figure 4A–C). This evidence concerns the gene TP53 and sarcoma.